Literature DB >> 3429386

Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

M B Carlier1, A Zenebergh, P M Tulkens.   

Abstract

The intracellular accumulation and subcellular distribution of 14C-labelled roxithromycin and erythromycin has been studied in macrophages and polymorphonuclear neutrophils of both human and animal origin. Roxithromycin was consistently and significantly more accumulated than erythromycin, reaching intracellular/extracellular concentration ratios between 14 (in polymorphonuclear neutrophils) and 190 (in alveolar macrophages from smokers). Uptake was reversible, insensitive to anaerobiosis and to the presence of an aminoglycoside, but inhibited by acid pH. Upon subcellular fractionation by isopycnic centrifugation in sucrose gradients., half the roxithromycin or erythromycin recovered in cell homogenates was found associated with the lysosomes in macrophages, and about one third with azurophil granules in polymorphonuclear leucocytes. Inasmuch as cellular uptake is a necessary, albeit not sufficient, condition for antimicrobials to kill or inhibit the growth of intracellular bacteria the properties of roxithromycin may give it a distinct advantage over other antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429386     DOI: 10.1093/jac/20.suppl_b.47

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

1.  In vitro uptake of SCH 27899 (evernimicin) by rat alveolar macrophages.

Authors:  S Zbaida; J Brieland; P Krieter; D Loebenberg; G Krishna; D Horne; X Lu; Y Yuan; R Hare; M N Cayen; J E Patrick
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Phagocytes, antibiotics and intracellular parasites: are the experimental data clinically relevant?

Authors:  J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

4.  Effect of various antibiotics on Listeria monocytogenes multiplying in L 929 cells.

Authors:  T Nichterlein; H Hof
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 6.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 7.  Phagocyte uptake and transport of azithromycin.

Authors:  P J McDonald; H Pruul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

Authors:  Françoise Van Bambeke; Stéphane Carryn; Cristina Seral; Hugues Chanteux; Donatienne Tyteca; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.